2019 PAINWeek Abstract Posters 1
Expert Consensus on the Optimization of Cannabinoids and Opioids for Chronic Pain Control
2
A Co-Crystal of Tramadol-Celecoxib in a 1:1 Molecular Ratio Produced Synergistic Antinociceptive Effects in a Postoperative Pain Model in Rats
3
The Unique Physiochemical Profile of Co-Crystal of Tramadol-Celecoxib Optimizes Pharmacokinetic and Pharmacodynamic Synchronization: Structural Properties, Differential Dissolution Behavior and Pharmacokinetic Parameters
4
Co-Crystal of Tramadol-Celecoxib: Efficacy and Safety Results from a Dose-Finding, Randomized, Double-blind, Multicenter, Phase II Clinical Trial in Patients with Moderate-To-Severe Acute Pain Due To an Oral Surgical Procedure
5
Implementation of Pragmatic Guidelines for Inpatient Opioid Management in a Regional Multi-Hospital System
6
Tolperisone, a Novel Muscle Relaxant, does not Impair Driving, While Cyclobenzaprine Results in Driving Impairment Potentially Due to Effects on Drowsiness
7
Ubrogepant Is Effective for the Acute Treatment of Migraine in Patients With an Insufficient Response to Triptans
8
The effect of food on the pharmacokinetic profile of a new abuse-deterrent oxycodone IR formulation compared to a marketed reference formulation
9 10
Evaluation of the intranasal abuse potential of a new abuse-deterrent oxycodone IR formulation compared to oxycodone powder Medication overuse in a post-hoc analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine
11
The Burden of Pain Symptoms: A prototype for citizens of British Columbia
12
Role of Tapentadol in Central Pain Condition: A Case Report
13
Exploratory in-vitro mastication to assess the potential accelerated release of Fentanyl from a transdermal patch
14
Opioid Use among People with Migraine: Results of the OVERCOME Study (2017-6229-002)
15
Cannabidiol: A Retrospective Review of Patient Outcomes for Pain, Sleep, Anxiety, Depression and Function
16
Does Cognitive Behavioral Therapy Increase Acceptance of Chronic Pain? A Practice-Based Evaluation amongst Veterans
17
An Examination of the Impact of Acceptance & Commitment Therapy on Pain-Related Acceptance in Veterans
18
A Randomized Control Trial of Multimedia Interventions to Improve Pain Education among Veterans with Chronic, Non-cancer Pain
19
Improved Functionality, Pain Relief, and Satisfaction in Patients Treated with Ubrogepant vs Placebo: Results from 2 Single-Attack Phase 3 Studies, ACHIEVE I and II
20
Functionality Study of the Pill-SafeTM Digital Health System to Assess Real Time Mechanical, Clinical Practicality, and Utility including Instantaneous Analytical Data on Drug Abuse Tendencies and Adherence: Alpha Usability Test
21
Exploration of Body Ownership, Agency and Heat Pain Perception in Virtual Reality (Vr)
22 23
A Serious Immersive Virtual Reality Game for Promoting Chronic Arthritis Pain Patients' General Physical Activity and Range Of Motion Does Immersive Virtual Reality Provide Modulate Chronic Pain: A Longitudinal Study Design
24
The design and evaluation of AS IF for sharing chronic pain patients’ experience in virtual reality settings
25
“I’ve got the power!” People in pain and their journey through coaching
26
Impact of Galcanezumab on Total Pain Burden: Findings from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache Features of Episodic Cluster Headache in the Real World Setting: Clinical Characteristics from a Large, Multi-National, CrossSectional Survey DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the acute treatment of episodic migraine: Efficacy results from two phase III randomized, double-blind, placebo-controlled studies
27 28 29
Safety and tolerability of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the acute treatment of episodic migraine: Safety results from two phase III randomized, double-blind, placebo-controlled studies
30
A Randomized, Controlled, Crossover Study to Assess the Abuse Potential of Lasmiditan
31
Safety and Efficacy of Lasmiditan in Patients with Cardiovascular Risk Factors: Results from Two Phase 3 Trials for Acute Treatment of Migraine Subcutaneous Tanezumab For Osteoarthritis: A 24-Week Phase 3 Study with A 24-Week Follow Up
32